These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30729353)

  • 1. Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81.
    Soares HR; Castro R; Tomás HA; Carrondo MJT; Alves PM; Coroadinha AS
    AMB Express; 2019 Feb; 9(1):22. PubMed ID: 30729353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetraspanins displayed in retrovirus-derived virus-like particles and their immunogenicity.
    Soares HR; Castro R; Tomás HA; Rodrigues AF; Gomes-Alves P; Bellier B; Klatzmann D; Carrondo MJT; Alves PM; Coroadinha AS
    Vaccine; 2016 Mar; 34(13):1634-1641. PubMed ID: 26795367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
    Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
    Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
    Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
    Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
    McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses.
    Seong YR; Choi S; Lim JS; Lee CH; Lee CK; Im DS
    Vaccine; 2001 Apr; 19(20-22):2955-64. PubMed ID: 11282207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.
    Owsianka A; Clayton RF; Loomis-Price LD; McKeating JA; Patel AH
    J Gen Virol; 2001 Aug; 82(Pt 8):1877-1883. PubMed ID: 11457993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.
    Ezelle HJ; Markovic D; Barber GN
    J Virol; 2002 Dec; 76(23):12325-34. PubMed ID: 12414973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.
    Earnest-Silveira L; Chua B; Chin R; Christiansen D; Johnson D; Herrmann S; Ralph SA; Vercauteren K; Mesalam A; Meuleman P; Das S; Boo I; Drummer H; Bock CT; Gowans EJ; Jackson DC; Torresi J
    J Gen Virol; 2016 Aug; 97(8):1865-1876. PubMed ID: 27147296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
    Allander T; Forns X; Emerson SU; Purcell RH; Bukh J
    Virology; 2000 Nov; 277(2):358-67. PubMed ID: 11080483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of hepatitis C virus E2 binding to CD81.
    VanCompernolle SE; Wiznycia AV; Rush JR; Dhanasekaran M; Baures PW; Todd SC
    Virology; 2003 Sep; 314(1):371-80. PubMed ID: 14517089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
    J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.
    Masavuli MG; Wijesundara DK; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Microbiol; 2017; 8():2413. PubMed ID: 29259601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].
    Ke JS; Zhao P; Cao J; Yu JP; Qi ZT
    Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):158-62. PubMed ID: 15966314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner.
    McKeating JA; Zhang LQ; Logvinoff C; Flint M; Zhang J; Yu J; Butera D; Ho DD; Dustin LB; Rice CM; Balfe P
    J Virol; 2004 Aug; 78(16):8496-505. PubMed ID: 15280458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.